SAN FRANCISCO--(BUSINESS WIRE)--Results of a Phase 2a clinical trial evaluating the potential of NKTR-061 (inhaled amikacin) to treat hospital acquired gram-negative bacterial pneumonia will be presented at the American Thoracic Society (ATS) International Conference, May 18 – 23, 2007, in San Francisco.
